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ABSTRACT
Purpose: p27Kip1 is a member of the Cip1/Kip1 family
of cyclin-dependent kinase inhibitors and is a potential tu-
mor suppressor gene. Low levels of p27 are associated with
poor prognosis in a variety of gynecological tumors, includ-
ing breast, ovarian, and cervical carcinomas. The role of p27
in endometrial cancer remains controversial.
Experimental Design: In the present study, p27 protein
expression was investigated by immunohistochemistry in a
series of 217 endometrial adenocarcinomas and, where pres-
ent, in synchronous normal endometrium, simple and com-
plex hyperplasia (with or without atypia), and cystic atro-
phy. The relationship between p27 expression and clinical
outcome was also evaluated.
Results: Immunohistochemical analysis revealed a sig-
nificant loss of p27 expression from normal (33%) through
hyperplastic endometrium (50%) to endometrial adenocar-
cinomas (71%; P < 0.001). In addition to nuclear staining,
cytoplasmic localization of p27 was noted in 193 (91%) of
217 specimens examined. When the clinical outcome of the
patients was evaluated in relation to p27 status, we found no
significant correlation between the presence of p27 staining
and clinicopathological parameters or survival.
Conclusions: These data indicate that p27 expression
could progressively decrease from normal endometrium
through hyperplastic endometrium to invasive endometrial
carcinomas, suggesting that loss of this tumor suppressor
may represent a novel and distinct molecular alteration
involved in estrogen-related endometrial adenocarcinomas
(type I). Despite the suggested role of the p27 protein in
determining the prognosis of several human tumors, it was
not found to be a predictor of clinical outcome in this large
group of patients with endometrial cancer.
INTRODUCTION
The eukaryotic cell cycle is controlled by protein kinase
complexes composed of cyclins and cdks.2 The activity of cdks
is regulated by binding of positive effectors, the cyclins, and by
association-dissociation of inhibitory subunits, designated CKIs
(1). Two families of cdk inhibitors have been identified. INK4
family members p15INK4B, p16INK4A, p18INK4C, and p19INK4D
bind to and inhibit cyclin D-dependent kinases cdk4 and cdk6
(2). Kip family members, including p21Cip1, p27Kip1, and
p57Kip2, preferentially inhibit cdk2 (1).
Cyclins, cdks, and CKIs are frequently altered in human
cancer (3). p27Kip1 is a CKI that regulates progression from G1
into S phase by inhibiting a variety of cyclin–cdk complexes,
including cyclin D–cdk4, cyclin E–cdk2, and cyclin A–cdk2.
The p27Kip1 gene is located on chromosome 12p and,
unlike the genes encoding INK4 family members, is rarely
affected by structural alterations in human malignancies (4).
Levels of p27 in human cancer, however, appear to be regulated
at the posttranslational level by ubiquitin-proteasome-dependent
degradation mechanisms (5, 6).
Endometrial cancer is the most frequent gynecological
malignancy of the female genital tract, accounting for 6% of all
cancers among women (7). Although the incidence of endome-
trial carcinoma has remained relatively stable during the past
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decade, the number of deaths annually from this disease has
more than doubled since 1987 (from 2900 to 6400 deaths).
During the last decade efforts have focused on attempting to
identify molecular events that correlate with the malignant po-
tential of this disease. The identification of markers predictive of
patients’ outcomes would assist clinicians in stratifying women
into risk groups. Great benefit is likely to result from the
characterization of additional prognostic factors that are more
closely related to tumor cell biology. These biological factors
may offer novel approaches to the identification of groups of
patients who could benefit from more aggressive therapy.
It is conceivable that most endometrial cancers occur as a
result of acquired alterations in oncogenes and tumor suppressor
genes that regulate signal transduction pathways involved in cell
proliferation and differentiation, as well as in cell cycle control.
Studies have shown that alterations in p53 (8), HER-2/neu (9),
bcl-2 (10), and Rb2/p130 (11) are associated with poor progno-
sis in endometrial cancer. Indicators of cell proliferation, such as
DNA ploidy (12), S-phase fraction, proliferative index, MIB-1
proliferation marker (13), and proliferating cell nuclear antigen
(14), have been evaluated.
Several studies demonstrated that loss of the p27Kip1 pro-
tein, as assessed by immunohistochemistry, is a negative prog-
nostic marker in some malignancies, including gynecological
cancers such as breast (15, 16), cervical (17), and ovarian cancer
(18, 19).
It has been shown that p27 expression is strongly reduced
in endometrial cancer (20–22). One recent study (23), however,
failed to find any association between p27 staining and clinico-
pathological parameters or survival in advanced endometrial
cancers. Another study (24) showed that p27 expression was
paradoxically associated with unfavorable clinicopathological
parameters in a large series of endometrioid adenocarcinomas.
Thus, the role of p27 in endometrial cancer remains controver-
sial.
In this study, we used immunohistochemistry to character-
ize the expression pattern of p27 Kip1 in 217 endometrial ade-
nocarcinomas and in other synchronous endometrial lesions,
including normal endometrium, simple and complex hyperpla-
sia with or without atypia, and cystic atrophy. We also evaluated
the relationship of p27Kip1 protein expression with clinicopath-
ological parameters and clinical outcomes in 193 patients with
endometrial adenocarcinoma.
MATERIALS AND METHODS
Patients and Tumor Specimens. We obtained 217 spec-
imens from previously untreated endometrial carcinoma patients
who underwent surgical resection in the Department of Gyne-
cology of the University of Florence (Florence, Italy) and at St.
Orsola Hospital, University of Bologna (Bologna, Italy). Patient
ages ranged from 28 to 93 years, with a median age of 64 years.
Histological classification of tumors was carried out according
to the WHO system, and tumors were graded as well (G1),
moderately (G2), and poorly (G3) differentiated. Clinical stages
of disease were established according to the 1989 FIGO system.
None of the patients had received chemotherapy or radiotherapy
before surgery. Those patients who were irradiated received 56
Gy postoperatively on the whole pelvis. Chemotherapy was
administered, when possible, to patients with more advanced
disease (stage III-IV). The chemotherapy regimen included cis-
platin (60 mg/m2) and epirubicin (60 mg/m2) every 21 days for
six cycles.
After completing the treatment, patients were seen every 3
months for the first 2 years, every 4 months during the 3rd and
4th years, and every 6 months thereafter. Recurrence was con-
sidered as any documented relapse of the tumor either in the
pelvis or systemically. DFS was calculated from the date of the
operation. Patients with residual disease after surgery or who
had a recurrence within 3 months of the date of the operation
were not considered free of disease and were excluded from the
disease-free analysis but not from actuarial survival calculation.
Patients with fatal outcomes other than from endometrial cancer
were considered to be lost at follow-up, and their survival time
was terminated on the date of death.
Flow Cytometric Analysis of DNA Index. In a sub-
group of 100 patients, a tumor specimen was taken fresh im-
mediately after hysterectomy and divided into two parts: one for
flow cytometric analysis and the other for histological confir-
mation. Flow cytometry was performed as described previously
(11). The DNA ploidy was provided by the DNA index, defined
as the proportion of the modal DNA values of the tumor cells in
G0 and G1 (peak channel) to the DNA content of the diploid
standard. The histograms were based on the measurement of
10,000 cells and generally resulted in a good resolution with
a coefficient of variation of 3–6%. Calculation of DNA index
was performed by processing each histogram with the com-
puter-assisted program Multicycle-Autofit, version 2.00 (Phoe-
nix Flow Systems, San Diego, CA).
All cases with a DNA index value of 1 (0.04) were
classified as diploid. The remaining cases were classified as
aneuploid.
Immunohistochemistry and Specificity of Immuno-
staining. After surgical resection, each tumor specimen was
immediately formalin-fixed and then paraffin-embedded for
Table 1 p27Kip1 distribution in endometrial cancer and synchronous endometrial lesions
Histology n
p27 staining (intensity score), n (%)
0–3 (negative/very low) 4–6 (low) 7–9 (moderate) 10–12 (high)
Normal endometrium 30 10 (33) 9 (30) 8 (27) 3 (10)
Hyperplasia without atypia 24 12 (50) 2 (8.5) 9 (37.5) 1 (4)
Atypical hyperplasia 5 5 (100)
Cystic atrophy 14 6 (42) 2 (14) 3 (21.5) 3 (21.5)
Adenocarcinoma 217 154 (71) 37 (17) 20 (9.3) 6 (2.7)
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routine and immunohistochemical investigation. Immunohisto-
chemistry was performed as described previously (19). Briefly,
the polyclonal antibody to p27Kip1 was incubated overnight with
tissue sections at a 1:150 dilution. Specificity of p27Kip1 staining
was assessed by preabsorption with the peptide used to generate
it. The staining pattern seen with the p27Kip1 polyclonal anti-
body was confirmed on duplicate slides using a monoclonal
antibody (Santa Cruz Biotechnology, Santa Cruz, CA). The
strong positive immunostaining of stromal cells in the sections
examined represented an internal positive control for preserva-
tion of p27 antigenicity in tissues. For the negative control, PBS
was substituted for the primary antibody.
pRb2/p130 staining in a subgroup of 100 patients was
performed as described previously (11).
p27 Scoring. Cells were scored for p27 staining accord-
ing to cellular compartmentalization. All immunoreactive cells
were considered positive. Three pathologists (C. M., D. M., and
G. T.) separately evaluated p27 staining in a coded manner, as
described previously (20). Every tumor and synchronous endo-
metrial lesion was assessed and given a score, obtained by
multiplying the intensity of the staining (no staining  0; low
staining  1; medium staining  2; strong staining  3) by the
percentage of cells stained (0%  0; 10%  1; 10–50%  2;
51–80%  3; 80%  4). The maximum score is 12 with this
system.
For the analysis of p27 according to clinicopathological
parameters and survival, protein levels were classified as posi-
tive (staining in 50% of cells) or negative (staining in 50%
of cells) as described previously (22). At least 20 high-power
fields were chosen randomly, and 2000 cells were counted.
Statistical Analysis. Fisher’s exact test for proportion
and the 2 test were used to analyze the distribution of p27-
positive specimens according to clinicopathological character-
istics. DFS and DRS were calculated according to the Kaplan–
Meier method and evaluated by the log-rank test. Univariate
Cox analysis was used to assess the effect of each prognostic
variable on DFS and DRS. A multivariate analysis (Cox pro-
portional hazards regression) was performed to estimate which
possible risk factors yielded independent prognostic informa-
tion. Data analysis was carried out using SPSS Statistical Soft-
ware, release 5.0.1 (SPSS Inc., Chicago, IL).
RESULTS
p27Kip1 Protein Expression in Normal Human Endo-
metrium, Simple and Complex Hyperplasia, and Cystic At-
rophy. The expression of p27Kip1 in endometrial tissues was
determined by immunohistochemistry. Lesions synchronous
with invasive carcinomas were classified as normal human
endometrium (n 30), simple and complex hyperplasia without
atypia (n  24), atypical hyperplasia (n  5), and atrophy
(n  14); their immunoreactivity for p27Kip1 is categorized in
Table 1.
Normal endometrium adjacent to the adenocarcinoma
showed positivity for p27 in the majority of specimens exam-
ined (67%; Fig. 1a). p27 immunostaining was mostly nuclear,
but weak cytoplasmic staining was also observed. Normal en-
dometrium was classified as proliferative in 3 cases, secretory in
11 cases, and inactive in the remaining samples (n  16). Lost
or decreased p27 expression was observed in inactive and pro-
liferative endometrium, whereas p27 was heterogeneously dis-
tributed in the secretory endometrium.
Simple and complex hyperplasia without atypia showed
loss of p27 in 12 of 24 samples (50%), whereas p27 staining was
lost in all specimens (5 of 5) of atypical hyperplasia (Fig. 1, b
Fig. 1 p27Kip1 immunostaining in normal endometrium, simple hyper-
plasia, and complex hyperplasia with atypia. a, p27 expression in
normal endometrium was detected in the nuclei of the cells, in the
superficial lining, and in the glandular cells in the functional layer. b,
simple hyperplasia shows a diffuse p27 reactivity in the nuclei as well
as in the cytoplasm of endometrial cells. c, complex hyperplasia with
atypia shows scattered p27-positive cells. Strong nuclear staining of
stromal cells is present in both hyperplasia specimens. Magnification,
40.
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and c). The pattern of p27 expression in cystic atrophy was
heterogeneous, with the presence of strong reactive nuclei in-
terspersed among cells with low or absent nuclear reactivity.
p27 Protein Expression in Endometrial Adenocarci-
noma. Immunoreactivity for p27 was also found in neoplastic
tissues (Fig. 2). A total of 217 endometrial tumor specimens
were evaluated. Endometrial adenocarcinomas expressed p27 in
63 of the 217 samples (29%; Fig. 2b), whereas the absence of
p27 protein expression was observed in the remaining 154
specimens (71%; Fig. 2, c and d). In contrast to normal endo-
metria, where p27 was localized mostly in the nuclei, endome-
trial adenocarcinomas showed concomitant and widely distrib-
uted cytoplasmic staining of p27Kip1 in 91% of the specimens
with or without concomitant nuclear staining (193 and 5 spec-
imens, respectively; Fig. 2, b and c).
In one specimen, p27 was present exclusively in the nuclei
of a focal area of the tumor. A statistically significant decrease
was found in p27 expression from normal (33%) to hyperplastic
endometrium with (100%) or without (50%) atypia, to endome-
trial adenocarcinomas (71%; P  0.001; Table 1).
Correlation of p27Kip1 Expression with Clinicopatho-
logical Parameters and Survival Analysis. We investigated
the distribution of p27-positive specimens according to a series
of clinicopathological parameters (age, FIGO stage, grading,
histotype, depth of myometrial invasion, adjuvant treatment,
ploidy status, S phase, DNA index, and pRb2/p130 expression)
obtained from 193 patients with endometrial adenocarcinoma
(Table 2). We found no correlation between p27 immunoreac-
tivity and known clinicopathological parameters regardless of
the p27 cutoff tested.
Follow-up data were available for 184 patients (median
follow-up, 34 months; range, 2–86 months). During the fol-
low-up period, progression and death from disease were ob-
served in 25 patients. p27-positive specimens (staining in50%
of cells) showed a more favorable prognosis than p27-negative
specimens (staining in 50% of cells), although no statistical
significance was reached; the 5-year DRS rate was 84% (95%
CI, 68–82%) for p27-positive specimens, compared with 73%
(95% CI, 64–72%) of p27-negative specimens (P  0.8213).
p27-positive cases also showed a 5-year DFS rate of 87.6%
(95% CI, 71–83%) compared with 72.8% (95% CI, 62–72%)
for p27-negative cases (P  0.5).
The prognostic roles of age at diagnosis, stage, histological
grade, depth of myometrial invasion, ploidy, and pRb2/p130 and
p27 Kip1 status were also tested with univariate Cox analysis for
both DRS and DFS (Table 3). Loss of p27 was associated with
Fig. 2 p27Kip1 immunostaining in four representative samples of endometrial adenocarcinomas. a, adenocarcinoma in situ. p27 expression is strongly
detected in the nuclei of cells in the outer lining, whereas most of the basal and parabasal cells show a weak nuclear staining. b, p27 is expressed in
90% of the neoplastic cells, which show a strong positive staining of the nuclei and a diffuse, faint cytoplasmic staining. c, p27 expression is decreased
in 50% of neoplastic cells, with scattered positive nuclei and a diffuse, faint cytoplasmic staining. d, endometrial carcinoma showing absent
expression of p27 in neoplastic cells and strong nuclear staining in stromal cells. Magnification, 40.
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a relative risk of dying of 1.67, although no statistical signifi-
cance was reached (P  0.18). Univariate Cox analysis also
showed that disease stage (P  0.0000), age (P  0.049),
histotype (P 0.046), depth of myometrial invasion (P 0.04),
DNA index (P  0.0000), tumor ploidy (P  0.0001), and
pRb2/p130 (P  0.0004) expression were significantly associ-
ated with DRS (Table 3). Expression of pRb2/p130 (P 
0.0029), stage (P  0.0002), histology (P  0.0067), DNA
index (P  0.0001), and tumor ploidy (P  0.0076) were also
significantly correlated with DFS according to univariate Cox
analysis (Table 3).
DISCUSSION
p27 belongs to the Kip (Kip1) family of CKIs and is
involved in multiple fundamental cellular processes, including
cell proliferation, cell differentiation, and apoptosis. Moreover,
p27Kip1 is a putative tumor suppressor gene that appears to play
a critical role in the pathogenesis of several human malignan-
cies, and its reduced expression has been shown to correlate
with poor prognosis in cancer patients (25).
We examined for the first time in this study the expression
of the cdk inhibitor p27Kip1 in a large cohort of endometrial
carcinomas and in synchronous normal endometrium, simple
and complex hyperplasia without atypia, atypical hyperplasia,
and cystic atrophy. Endometrial adenocarcinoma may originate
from either hyperplastic or atrophic (postmenopausal) endome-
trium; the former (type I) is related to hyperestrogenism, and the
latter (type II) is independent of direct hormonal effects. Al-
though the estrogen-independent pathway has been consistently
associated with p53 mutation (26) and overexpression (27), the
molecular alterations underlying estrogen-related carcinomas
have not been fully elucidated.
We previously reported (11, 28) that the Rb family member
pRb2/p130 is an important prognostic factor involved in the
biology of type I endometrial carcinomas. Our finding of a
progressive decrease in p27Kip1 expression from normal through
hyperplastic endometrium to atypical hyperplasia and endome-
trial adenocarcinomas suggests the involvement of this negative
cell cycle regulator in type 1 endometrial carcinogenesis. Al-
though our study was limited to endometrial lesions that were
synchronous and not independent from the invasive carcinomas,
this hypothesis is consistent with previous data. In particular,
p27Kip1 expression is negligible in hyperplastic epithelium,
whereas it is greatly increased after treatment with medroxypro-
gesterone acetate (29), and targeted inactivation of p27 leads to
the development of multiple organ hyperplasia (30, 31), includ-
ing abnormal endometrial proliferation (31). It then could be
hypothesized that p27 protein levels, under physiological con-
ditions, are hormonally controlled, with estrogens decreasing
expression and progestins counteracting this effect.
The loss of p27 expression in 100% of the cases of atypical
hyperplasia is intriguing and in agreement with the precancerous
features of this endometrial lesion; however, such a result de-
serves to be confirmed in a larger number of cases because of
the small number of samples analyzed in our study (n  5).
The high percentage of endometrial carcinomas exhibiting
loss of p27 protein expression may imply an important role for
p27 in the pathogenesis of this neoplasm and is consistent with
recent data (32) showing that both p27 nullizygous and het-
erozygous mice are predisposed to develop tumors in multiple
tissues, including endometrial adenocarcinomas, when exposed
to carcinogens or gamma irradiation. Because of the lack of p27
cancer-specific mutations in human tumors (33), it is conceiv-
able that loss of p27 expression in endometrial cancer may result
from increased degradation of the protein mediated by the
ubiquitin proteasome pathway, as observed previously in other
malignancies (6, 15, 34).
Subcellular compartmentalization of p27 has been ob-
served previously in normal prostate tissue, dysplastic Barrett’s
epithelium, and colorectal (9, 14), ovarian (18, 19), and esoph-
ageal cancer (35). It is interesting to note that p27 expression in
our series was frequently cytoplasmic (with or without concom-
itant nuclear staining). Although recent studies showed that
cytoplasmic dislocation of p27 has a prognostic role in several









65 66 (34) 42 (21.7) NSa
65 58 (30) 27 (14)
FIGO stage 193
I 92 (47.6) 58 (30) NS
II 15 (7.7) 6 (3.1)
III 14 (7.2) 4 (2)




96 (49.6) 46 (23.8) NS
Adenosquamous 17 (8.8) 11 (5.6)
Clear cell 1 (0.5) 6 (3.1)
Adenoacanthoma 1 (0.5) 2 (1)




Squamous cell 1 (0.5)
Undifferentiated 1 (0.5)
Grading 178
G1 46 (25.8) 24 (13.4) NS
G2 49 (27.5) 24 (13.4)




50% of depth 63 (32.6) 35 (18.1) NS
50% of depth 61 (31.6) 34 (17.6)
Adjuvant treatment 109
None 41 (37.6) 17 (15.6) NS
Radiotherapy 31 (28.4) 13 (11.9)
Chemotherapy 6 (5.5) 1 (0.9)
Ploidy status 109
Diploid 60 (55) 24 (22) NS
Aneuploid 18 (16.5) 7 (6.4)
S phase 106
5 29 (27.3) 10 (9.4) NS
5 47 (44.3) 20 (18.8)
DNA index 109
1.5 67 (61.5) 27 (24.7) NS
1.5 11 (10) 4 (3.7)
pRb2/p130 84
40% 47 (56) 14 (16.7) NS
40% 18 (21.4) 5 (5.9)
a NS, not significant.
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tumors (35, 36), we and others (23, 24) failed to find a correlation
between p27 cytoplasmic staining and clinical outcome in endo-
metrial cancer. The mechanism responsible for this phenomenon
and its biological significance in these tumor cells continues to
remain poorly understood. However, it is noteworthy that cytoplas-
mic displacement of p27 is regulated by phosphorylation on Ser-10
(37) and has been linked to binding to a transcriptional activator,
such as Jab1 (38) or to phosphorylation by AKT (39).
We have demonstrated low p27Kip1 expression (score of 0–3)
in 71% of the endometrial cancers studied. However, we observed
no correlation between p27Kip1 protein levels and known clinico-
pathological variables. This result is in agreement with previous
observations (20, 21, 23) but seems to be in contrast to a recent
study (24), which found a paradoxical correlation between high p27
expression and unfavorable prognostic factors, such as high FIGO
stage, lymph node metastasis, lymphovascular space involvement,
and myometrial invasion in a series of 127 patients with endometri-
oid adenocarcinomas. The use of a different antibody, the selected
histotype of patients (endometrioid adenocarcinomas only), and the
smaller number of specimens analyzed may account for the results
in the previous study (24), which differ from our report involving
a large cohort study of unselected patients. Moreover, to avoid
additional differences between studies, highly sensitive and repro-
ducible techniques, such as automated quantitative computer-
assisted analysis of immunohistochemical expression of markers,
should be used.
Decreased p27 expression has been shown to be an indepen-
dent negative predictor of prognosis in several tumor types (15, 16,
19, 25). In our group of 184 patients, p27 had no independent
prognostic significance. We could only demonstrate reduced 5-year
DRS and DFS in patients with decreased p27Kip1 expression (stain-
ing in 50% of cancer cells) compared with those patients with
high p27 expression (staining in 50% of cancer cells). However,
this difference was not statistically significant. This is consistent
with a previous study by Nycum et al. (23), who found no asso-
ciation between p27 staining and survival in 24 advanced-stage
patients with endometrial carcinoma.
In conclusion, although loss of p27Kip1 appears to be a
frequent event in endometrial cancer, immunohistochemical de-
termination of p27 expression does not seem to contribute to a
better prediction of prognosis in this large cohort of patients
with endometrial adenocarcinoma.
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